Morphologic examination by light microscopy remains an integral part of initial histopathologic assessment for hematolymphoid neoplasms; however, a variety of laboratory techniques are now being used to optimize diagnostic information in the appropriate clinical context. For diagnosing myeloid disorders and acute myeloid leukemia, one approach is to utilize an next gen sequencing panel and DNA-based cytogenomic microarray, according to Dr. Pranil Chandra, Chief Medical Officer of Genomic and Clinical Pathology with PathGroup. In this CAPcast, Dr. Chandra discusses why his laboratory, in conjunction with pathologist and oncologist colleagues, developed this technology and how they’ve implemented it into clinical practice.

Dr. Chandra currently serves on the Personalized Healthcare Committee of the College of American Pathologists, and he’s written a short article now posted on CAP.org (https://capatholo.gy/2RO4h96) outlining the reasoning his team used to make this panel their standard of care.